Fig. 4

ATL-55T and LMY1 cell lines are sensitive to NSC 617145. a HTLV-1-transformed (MT-4, C8166, C91PL, 1186.94) and ATL-derived (ED, TL, ATL-25, ATL-43T, ATL-55T, LMY1, KK1, SO4, KOB) cell lines and normal resting PBMCs were treated with increasing doses of NSC 617145 (0.02, 0.2, 2, and 20 μM). Inhibition of cellular growth was measured by using cell count. Experiment was performed multiple times in duplicate. Representative results are shown in the final figures. b Patient-derived cell line, ATL-55T, was exposed to increasing amounts of NSC 617145 for 4 days, and the anti-proliferative effect was evaluated by cell count and XTT assay. Representative results are shown in the final figures. P values were calculated using paired two-sided Student’s t test. c LMY1-ATL-derived cells were treated with 0.25 μM of NSC 617145 for 96 h and stained with crystal violet. Cell count and XTT assay were used to measure the cellular growth of NSC 617145-treated cells compared to DMSO control cells. Experiment was performed multiple times in duplicate. Representative results are shown in the final figures. P values were calculated by using paired and two-tailed Student’s t test and indicated in the figure. d ATL-55T and LMY1 cells were stained with annexin V to measure the apoptotic effect of the WRN helicase inhibitor NSC 617145. Cells were treated for 92 h with 0.25 μM of NSC 617145. e The figures include the percentage of cells in the four quarters: Q1, Q2, Q3, and Q4. Q3 included the live cells that are annexin V and PI negative. Q4 included early apoptotic cells, which are annexin V positive and PI negative. Q2 included cells in late apoptosis, which are both annexin V and PI positive. Finally, Q1 included necrotic cells, which are PI positive and annexin V negative. Experiment was performed multiple times in duplicate. Representative results are shown in the final figures